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Abstract
Precise cellular targeting of macromolecular cargos has
important biotechnological and medical implications. Using a
recently established ‘protein stapling’ method, we linked the
proteolytic domain of botulinum neurotoxin type A (BoNT/A)
to a selection of ligands to target neuroendocrine tumor cells.
The botulinum proteolytic domain was chosen because of its
well-known potency to block the release of neurotransmitters
and hormones. Among nine tested stapled ligands, the
epidermal growth factor was able to deliver the botulinum
enzyme into pheochromocytoma PC12 and insulinoma
Min6 cells; ciliary neurotrophic factor was effective on
neuroblastoma SH-SY5Y and Neuro2A cells, whereas
corticotropin-releasing hormone was active on pituitary AtT-
20 cells and the two neuroblastoma cell lines. In neuronal
cultures, the epidermal growth factor- and ciliary neurotrophic
factor-directed botulinum enzyme targeted distinct subsets of
neurons whereas the whole native neurotoxin targeted the
cortical neurons indiscriminately. At nanomolar concentra-
tions, the retargeted botulinum molecules were able to inhibit
stimulated release of hormones from tested cell lines
suggesting their application for treatments of neuroendocrine
disorders.
Keywords: botulinum, growth factor, neuroendocrine tumor,
neuropeptide, SNAP25, targeting.
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Neuroendocrine tumors (NETs) arise from cells of the
endocrine and nervous systems. NETs are present not only in
endocrine glands that secrete hormones but can also be
localized throughout the body, for example, in the gastroin-
testinal tract, pancreatic islets, adrenomedulla, thymus,
pituitary and lung tissues (Langley 1994). NETs can also
arise from Schwann cells and neurons, forming schwanno-
mas and neuroblastomas. Despite different embryological
lineages, NETs have similar phenotypic characteristics and
often exhibit excessive secretion of various neurotransmitters
and hormones (Bajohrs et al. 2005; Ferolla et al. 2008). It is
well known that excessive release of catecholamine, acetyl-
choline, insulin, and corticotropin from NETs can wreak
havoc on endocrine homeostasis and thus new approaches to
control secretory activity of neuroendocrine cells are urgently
required (Batcher et al. 2011; Prejbisz et al. 2011; Kirmani
2012; Kroesen et al. 2012; Low et al. 2012; Tritos and Biller
2012). Here, we used a botulinum-based strategy to inves-
tigate targeting of a selection of widely used model
neuroendocrine cells: mouse neuroblastoma (Neuro2a), ins-
ulinoma (Min6), pituitary adenoma corticotrophs (AtT-20),
rat pheochromocytoma (PC12), and human neuroblastoma
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(SH-SY5Y) cells (Schiavo et al. 2000; Foster et al. 2006;
Foster and Chaddock 2010; Pickett and Perrow 2011;
Davletov et al. 2012).
Secretory activity of neuroendocrine cells and neurons
relies on soluble N-ethylmaleimide sensitive fusion protein-
attachment protein receptors (SNAREs): syntaxin 1, syn-
aptosomal-associated protein 25 (SNAP25), and synaptob-
revin (Fasshauer et al. 1998; Sutton et al. 1998; S€udhof
and Rothman 2009; Gao et al. 2012). These three proteins
form a tight complex that allows fusion of secretory
vesicles with the plasma membrane in both neurons and
endocrine cells. Botulinum neurotoxin type A (BoNT/A),
produced by a Clostridium bacterium carries a protease that
selectively cleaves SNAP25 thereby blocking neuronal
secretion for several months (Meunier et al. 2003; Davletov
et al. 2005). The native BoNT/A recognizes speciﬁcally
neurons via its receptor-binding domain and can then
deliver its SNAP25 protease into the intra-neuronal envi-
ronment (Yowler et al. 2002; Mahrhold et al. 2006; Binz
and Rummel 2009). As neuroendocrine cells lack neuron-
speciﬁc gangliosides, NET cells are normally resistant to
the external application of BoNT/A (Yowler et al. 2002).
However, in experimental settings, expression or delivery
of the botulinum protease into NET cells leads to SNAP25
cleavage resulting in the blockade of hormonal secretion
(Chaddock et al. 2000a,b; Bajohrs et al. 2004; Foster et al.
2006). Here, we address the possibility to deliver the
botulinum protease to NET cells using a selection of
growth factors and neuropeptides by exploiting a novel
protein stapling method.
The most straightforward strategy for targeting a bacterial
enzyme into desired cells would be to directly fuse it to a
chosen ligand, provided the ligand is amenable for bacterial
expression and the new structure permits receptor binding. In
the case of the botulinum protease, its large size, its
dependence on additional structural units for translocation
into the neuronal cytosol, and its variable production yields
forced us to explore a new approach. We recently introduced
a so-called ‘protein stapling’ technology where a complex
protein can be produced independently and then ‘stapled’ to
a targeting unit (Darios et al. 2010; Ferrari et al. 2012). We
demonstrated that the BoNT/A1 Botulinum enzymatic and
Translocation domains (BoT), linked by a disulﬁde bond,
could be functionally produced in E.coli as required for
stapling (Darios et al. 2010). Here, we prepared a range of
growth factors: epidermal growth factor (EGF), tumor
necrosis factor a (TNFa), ciliary neurotrophic factor
(CNTF); and neuropeptides: dermorphine (Dermo), dynor-
phin 17 (Dyn17), corticotropin-releasing hormone (CRH),
substance P (SP), somatostatin, for parallel stapling to our
standardized botulinum construct.
Our side-by-side tests on a selection of NETs demon-
strated that growth factors and neuropeptides could target
distinct tumor cells with the internalization of the botulinum
enzyme evidenced by proteolysis of the SNAP25 protein
responsible for exocytosis of neurotransmitters and hor-
mones. The observed cell selectivity was further conﬁrmed
using BoT directly fused with the EGF and CNTF ligands,
which could be produced in E. coli as fusion proteins. Our
results show that the stapling technology allows not only
parallel production of functional biological molecules but
also their greater diversity in exploration of cell-targeting
strategies.
Materials and methods
Protein production and stapling reactions
All proteins were expressed in the BL21 strain of E. coli as
glutathione S-transferase C-terminal fusions cleavable by thrombin.
The Botulinum light chain and Translocation domain (BoT) of the
botulinum type A1 strain fused to SNAP25 (Staple), and the
syntaxin peptide (stapling peptide) were prepared as previously
described (Darios et al. 2010; Ferrari et al. 2012). The growth
factors and neuropeptides’ DNA were synthesized by Eurogentec
(Belgium) and cloned into pGEX-KG vectors. The plasmid for
expression of synaptobrevin-fused ligands were generated as
follows: rat synaptobrevin 2 (amino acids 25–84) was inserted into
the pGEX-KG vector between BamHI and EcoRI sites and the DNA
sequences for human CRH (1–41), EGF (1–53), CNTF (1–200),
dynorphin (1–17), and TNFa (57–233), each carrying a preceding
double repeat GGSGG spacer sequence, were inserted into the XhoI
site at the 3′ end of the synaptobrevin sequence. Rat syntaxin 3
(195–253) was used to construct the syntaxin-linked CRH in the
same manner. For direct fusion to the BoT protein, CNTF, CRH,
EGF, TNFa, and SP (1–11) were inserted between two XhoI sites in
the pGEX-KG vector carrying the BoNT/A (1–872) sequence
(Darios et al. 2010). All inserted DNAs were veriﬁed by sequencing
using pGEX-3 and pGEX-5 primers (Source Bioscience, Notting-
ham, UK). Proteins were expressed and puriﬁed as previously
described (Darios et al. 2010). Protein concentrations were deter-
mined using BCA Protein Assay Kit (Thermo scientiﬁc, Loughbor-
ough, UK). Syntaxin-SP (Ac-EIIKLENSIRELHDMFMDMAML
VESQGEMIDRIEYNVEHAVDYVE-Ahx-Ahx-RPKPQQFFGLM-
NH2), synaptobrevin-SP (Ac-RLQQTQAQVDEVVDIMRVNV
DKVLERDQKLSELDDRADALQAGAS-Ahx-Ahx-RPKPQQFF
GLM-NH2), synaptobrevin-somatostatin (sequence: Ac-RLQQ
TQAQVDEVVDIMRVNVDKVLERDQKLSELDDRADAL-Ahx-
Ahx-AGCKNFFWKTFTSC-OH), dermo-synaptobrevin (Y(D-Ala)
FGYPS-Ahx-Ahx-RLQQTQAQVDEVVDIMRVNVDRVLERDQ
RLSELDDRADALQAGAS-NH2) were prepared by Peptide Syn-
thetics UK, dissolved in dimethyl sulfoxide, and diluted in Buffer A
(100 mM NaCl, 20 mM HEPES, pH 7.4) to 1 mg/mL. Assembly
reactions were performed in Buffer A supplemented with 0.4%
n-octyl-b-D-glucopyranoside (Calbiochem, San Diego, CA, USA)
with ratios of BoT-Staple/stapling peptide/ligand at 5 : 7 : 7.
Protein assembly reactions were at 20°C for 1 h. Sodium dodecyl
sulfate-resistant, and irreversibly assembled protein complexes were
conﬁrmed on sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS–PAGE) gels migrated at 4°C. Proteins were added to
cell cultures and incubated for 42 h. In competition assays an excess
of ligand was incubated 15 min prior to the administration of the
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botulinum compounds. Human EGF was from Roche (Burgess Hill,
UK) and human CNTF was from Invitrogen, Paisley, UK.
Cell culture
Cells were grown in a 37°C incubator at 5% CO2. Neuro2A and SH-
SY5Y cells were grown in low glucose Dulbecco’s Modiﬁed Eagle
Medium (DMEM, Gibco, Rockville, MD, USA) supplemented with
10% fetal calf serum (FCS Fetalclone1, HyClone) and 1%
Penicillin/Streptomycin (P/S, Invitrogen). Every 3–4 days, cells
were washed with Phosphate Buffer Solution (PBS) and resus-
pended in culture medium using ﬂow pressure, then counted using a
hemacytometer. Cells were plated in at 1 9 106 cells per 9 cm
culture dish (BD Falcon) or at 1 9 105 cells per well in uncoated
24-well plates (BD Falcon). PC12 cells were grown in low glucose
DMEM supplemented with 10% equine serum (ES, HyClone), 5%
FCS and 1% P/S in pre-coated type IV collagen coated 75 cm2
ﬂasks (BD bioscience, San Jose, CA, USA). Cells passage was
passed once per week and the medium changed at midpoint between
passages. During passage, cells were washed in PBS, then treated
with trypsin, and plated at 3 9 106 cells per ﬂask or at 2 9 105 cells
per well on poly-L-lysine (Invitrogen) and collagen (Invitrogen)
25 : 1 coated 24-well plates. Min6 cells were grown in high glucose
DMEM supplemented with 15% FCS, 1% P/S and 250 nM
b-mercaptoethanol (VWR International, Lutterworth, UK). Cells
were passed every 3–4 days, trypsin-treated and plated at 1.5 9 106
cells per 9 cm culture dish or 1.5 9 105 cells per uncoated 24-well
plates. AtT-20 cells were grown in F12K medium supplemented
with 15% ES, 2.5% FCS and 1% P/S. Cells were passed every
3–4 days and grown in suspension in uncoated 75 cm2 culture
ﬂasks (BD Falcon, San Jose, CA, USA) or plated at 2 9 105 cells
per well on poly-L-lysine/collagen 25 : 1 coated 24-well plates.
Sprague–Dawley rat primary cortical neurons were prepared as
previously reported (Darios et al. 2010). Brieﬂy, embryonic day 16
brain cortices were dissected and the tissue incubated in papain
(Worthington, Lakewood, NJ, USA) for 20 min at 37°C. Following
dissociation, the suspension was ﬁltered, centrifuged and precipi-
tated cells plated at the density of 1 9 105 cells/well in 24-well
plates coated with poly-D-lysine 50 lg/mL (Sigma-Aldrich, Dorset,
UK) and laminin 20 lg/mL from Engelbreth-Holm-Swarm murine
sarcoma basement membrane (Sigma-Aldrich), with or without
glass coverslips. Cells were maintained in Neurobasal medium
(Gibco) supplemented with 1% B27 (Gibco), 1% P/S, and 400 lM
L-glutamine (Gibco). Half of the medium was changed every
3–4 days and cultures were tested at least 1 week after plating and
kept for a maximum of 4 weeks.
Immunostaining and confocal microscopy
Cells grown on coated coverslips in 24-well plates were treated with
or without BoT molecules 42 h before being ﬁxed in 4%
paraformaldehyde in PBS for 20 min at 20°C. The cells were
further washed three times with PBS for 5 min and incubated
10 min in 10 mM NH4Cl. The cells were then incubated for 30 min
in a permeabilization solution composed of 0.1% Triton X-100, 5%
bovine serum albumin (BSA, Sigma-Aldrich) in PBS. Permeabili-
zation solution was then replaced with 5% BSA in PBS containing
appropriate primary antibodies. Mouse monoclonal anti-SNAP25
(SMI81, Novagen, Feltham, UK), rabbit polyclonal anti-cleaved
SNAP25 antibody (Ekong et al. 1997; Antonucci et al. 2008;
Ferrari et al. 2011), and mouse monoclonal anti-MAP2 (clone
AP20, Millipore, Feltham, UK) were used at 1 : 500 dilutions. The
wells were washed three times in PBS, then incubated for 30 min
with Alexa Fluor 488 goat anti-mouse IgG and/or Alexa Fluor
594 goat anti-rabbit IgG diluted 1 : 800 in 5% BSA in PBS. Wells
were washed three times with PBS. Coverslips were overturned onto
Vectashield mounting medium, sealed, and visualized on Zeiss 710
confocal microscope at 639 and 209 magniﬁcation. The ﬂuorescent
gain intensities and pinhole size (1AU) were identical between
experimental samples. Colocalization was quantiﬁed using the Zeiss
software (Carl Zeiss Ltd., Cambridge, UK). Pictures for quantiﬁ-
cation were taken from random ﬁelds in three different regions of
each glass coverslips.
Western immunoblotting
Following treatment of cells with BoT molecules for 42 h, the wells
were washed once with PBS before addition of 100 lL of loading
buffer (56 mM sodium dodecyl sulfate, 0.05 M Tris-HCl, pH 6.8,
1.6 mM UltraPure EDTA (Gibco, Paisley, UK), 6.25% glycerol,
0.0001% bromophenol blue). One unit of benzonase (Novagen)
supplemented with 1 lL of 1 M MgCl2, was added to each well and
plates were shaken at 1500 rpm for 10 min. Samples were boiled
for 1 min at 95°C and then run on 12% Novex SDS–PAGE gels
(Invitrogen). Running time was doubled for SMI81 blotting to better
visualize both cleaved and intact SNAP25. Following separation,
proteins were transferred onto Immobilin-P polyvinylidene diﬂuo-
ride membranes, and then incubated for 30 min in blotting solution
(5% milk, 0.1% TWEEN 20 in PBS). The above-mentioned primary
antibodies and rabbit polyclonal anti-syntaxin 1b (Synaptic Systems,
Goettingen, Germany) were added at 1 : 3000 dilutions to the
blotting solution and incubated for 1 h. Membranes were washed
three times in 0.1% TWEEN 20 in PBS for 5 min and then
incubated for 30 min in the blotting solution containing secondary
peroxidase-conjugated goat anti-mouse or anti-rabbit antibodies
(Thermo Scientiﬁc), respectively. Membranes were washed three
times for 5 min in 0.1% TWEEN 20 in PBS. Immunoreactive
protein bands were visualized using SuperSignal West Dura
Extended Duration solution (Thermo Scientiﬁc, Cramlington, UK)
with exposure to Fuji Medical X-Ray ﬁlms (Fuji, Ross-on-wye,
UK). Band intensities were quantiﬁed as previously described
(Arsenault et al. 2010).
Release assays
3H-norepinephrin release assay was performed as described
elsewhere (Taupenot 2007). Brieﬂy, 2 9 105 PC12 cells were
grown on poly-L-lysine and collagen-coated 24-well plates and
incubated with BoT molecules for 42 h. Cells were incubated with
3H-norepinephrin (Perkin Elmer, Waltham, MA, USA) for 90 min
at 37°C in the complete medium, washed with pre-warmed basal
buffer (150 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM HEPES,
pH 7.4) and then stimulation was triggered using potassium
chloride buffer (100 mM NaCl, 55 mM KCl, 2 mM CaCl2,
10 mM HEPES, pH 7.4) for 15 min. Medium was removed for
scintillation radioisotope counting. Remaining cells were resus-
pended in the basal buffer supplemented with 0.2% Triton X-100.
All samples were mixed with scintillation ﬂuid (4 : 1 ratio) and
counted with Perkin Elmer Tri-Carb 2910TR liquid scintillation
counter. Percentage of release was equal to soluble fraction
© 2013 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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(released) divided by the sum of the soluble fraction and the
insoluble fraction (unreleased). ACTH release was performed
using an enzymatic immunoassay kit (EIA, Pheonix Pharmaceu-
ticals, Karlsruhe, Germany). Brieﬂy, AtT-20 cells were treated
with the botulinum molecules for 42 h before assay were washed
twice with the basal buffer, and then incubated for 10 min at 37°C
either in a pre-warmed incomplete F12K medium (basal condition)
or pre-warmed incomplete F12K medium supplemented with
10 lM bovine CRH (Sigma-Aldrich; stimulated condition). Media
were removed, brieﬂy centrifuged, and supernatants were added to
96-well immunoassay plates pre-coated with secondary antibody.
The released adrenocorticotropic hormone (ACTH) peptide
competes for a biotinylated ATCH peptide with the primary
antibody and signal is revealed by a decrease in bound strepta-
vidin-horseradish peroxidase. All data points were performed in
triplicate.
Statistical analysis
All experiments were performed at least in triplicate. Results are
presented as mean  standard deviation (SD). Data analysis was
performed using Graphpad Prism 5.0 (La Jolla, CA, USA). The
unpaired 2-tailed Student’s t-test was used for comparison. A
p value of < 0.05 was considered statistically signiﬁcant.
Results
Retargeting the botulinum protease
A schematic representation of the protein stapling technique
is outlined Fig. 1a, where the BoT (aa 1-872) portion of the
BoNT/A1 is stapled to the native receptor-binding domain of
BoNT/A1, resulting in a functional neuronal blocking
construct (Darios et al. 2010). In a similar fashion, new
targeting domains were attached to the BoT unit to target the
cognate cell surface receptors (Fig. 1b). The assembly of
diverse targeting domains with the BoT unit was visualized
in a Coomassie-stained SDS–PAGE gel (Fig. 1c).
Cleavage of cellular SNAP25 by targeted botulinum
constructs
The SNAP25 protein, responsible for hormone secretion and
located on the inner leaﬂet of the plasma membrane, can be
visualized in ﬁve tested NET cells (pheochromocytoma
PC12, insulinoma Min6, neuroblastomas SH-SY5Y and
Neuro2A, and pituitary AtT-20) (Fig. 2a). The targeted BoT
versions were incubated with the cells for 42 h and the
intracellular cleavage of SNAP25 was examined using a
(a)
(b)
(c)
Fig. 1 The protein stapling technique used for cell targeting. (a)
Schematic representation of protein stapling using the Botulinum
enzymatic and translocation domains (BoT) (the protease domain,
brown; the translocation domain, red, and a SNAP25 linker, green), the
native receptor-binding domain (Hc) (yellow, contains a synaptobrevin
linker) and the stapling peptide (syntaxin-derived, blue). Addition of the
stapling peptide results in formation of an irreversible botulinum
construct (Bitox). (b) A diagram showing the cell targeting approach
utilizing a range of ligands. (c) Coomassie-stained sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gel showing an array of
BoT-Staple-constructs carrying the indicated targeting domains: ciliary
neurotrophic factor (CNTF); tumor necrosis factor a (TNF-a); epidermal
growth factor (EGF), corticotropin releasing hormone (CRH), sub-
stance P (SP), double substance P (2 9 SP); somatostatin (SS);
dermorphin (Dermo); dynorphin 17 (Dyn17). BoT-Staple is a control
construct without a targeting moiety.
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polyclonal antibody that recognizes only its cleaved end,
speciﬁcally the TRIDEANQ amino acid sequence (Fig. 2b)
(Ekong et al. 1997). Because we have used the same starting
concentration of the BoT unit, the difference in SNAP25
cleavage was exclusively because of the efﬁciency of the
ligands to target cells, and delivered the botulinum protease
into the cytosol of NET cells. The latter step involves
internalization of the cognate receptors, a pH-dependent
translocation of the botulinum protease, and the protease
activity itself (Schiavo et al. 1993; Binz and Rummel 2009).
We observed that Bitox, which carries the native BoNT/A
targeting domain, could cleave SNAP25 in SH-SY5Y
neuroblastoma cells, which is in accord with the ability of
native BoNT/A to target these cells (Darios et al. 2010;
Thirunavukkarasusx et al. 2011). BoT constructs stapled to
CNTF (aa 1-200) and CRH (aa 1-41) were able to cleave
SNAP25 in SH-SY5Y cells as efﬁciently as Bitox while EGF
exhibited a lower targeting capacity (Fig. 2b). In the Min6
insulinoma cells the pattern changed, the BoT-Staple-EGF
was as efﬁcient as Bitox whereas CNTF and CRH moieties
were less effective. It has been reported that insulinoma cells
are refractory to BoNT/A binding (Boyd et al. 1995);
however, our highly sensitive cleaved-SNAP25 immunoas-
say does reveal some efﬁcacy of botulinum-based targeting
(Bitox) (Fig. 2b). In the Neuro2A cells, CNTF and CRH
targeted BoT better than the native botulinum targeting part
(Bitox) in agreement with a reduced ability of native BoNT/
A to bind these cells (Yowler et al. 2002). In the PC12
pheochromocytoma cells, BoT-Staple-EGF was most efﬁ-
cient with somatostatin and dermorphin exhibiting next in
rank efﬁciency. Interestingly, C-terminally amidated sub-
stance P and dermorphin demonstrated a signiﬁcant activity,
as well as CRH-linked BoT, suggesting the presence of
cognate receptors in these cancer cells. Finally, in the AtT-20
adenoma cells the CRH-directed complex was far superior to
other ligands as would be expected from pituitary cortico-
troph cells (Fig. 2b).
Fully recombinant EGF and CNTF botulinum chimeras
validate the observed cell specificity of the targeting
domains
Next, we recombinantly fused CNTF, EGF, CRH, TNFa,
dynorphin 17, and substance P to the C-terminal end of the
BoT unit. We did not prepare fusion of dermorphin as it
requires free N-terminus for binding to opioid receptors
(Amiche et al. 1988). Fusion of ligands to the original BoT
unit led a 3- to 10-fold drop in protein yields (0.5–1.5 mg per
liter of bacterial culture), while BoT-CRH and BoT-dynor-
phin 17 were not produced at detectable levels. Fig. 3a
shows migration pattern of the recombinantly fused chimeras
on a Coomassie-stained SDS–PAGE gel. Analysis of
SNAP25 cleavage following their application (10 nM) for
42 h on the NET cells demonstrated similar pattern of
activity compared to the stapled BoT molecules (Figs. 3b
and 2b). In human SH-SY5Y cells, BoT-CNTF has a
superior efﬁcacy closely followed by BoT-EGF. Min6 cells
display a reverse trend with BoT-EGF being superior.
Neuro2A, PC12 and AtT-20 cells also exhibited SNAP25
cleavage in a speciﬁc way when treated with the EGF- and
CNTF-BoT fusions. Overall, we conclude that when direct
recombinant fusions can be obtained, the targeted BoT
molecules show similar targeting pattern to that obtained
with the stapled products. We did not observe a SNAP25
cleavage with the BoT-substance P fusion protein, as would
(a)
(b)
Fig. 2 Targeting of neuroendocrine tumor cells using stapled botu-
linum constructs. (a) SNAP25 expression visualized by immunocyto-
chemistry in the indicated cells: human neuroblastoma SH-SY5Y,
mouse insulinoma Min6, mouse neuroblastoma Neuro2a, rat pheo-
chromocytoma PC12, and mouse pituitary adenoma corticotroph AtT-
20 cell. (b) Western blotting of the cleaved SNAP25 product in tested
cells reveals selective botulinum activity for newly designed constructs.
Untargeted Botulinum enzymatic and translocation domains (BoT)-
Staple was used as a control, followed by Bitox and ligand-targeted
BoTs as indicated in Fig. 1c. Total syntaxin immunoreactivity, shown
here for SH-SY5Y cells, was routinely used as a loading control.
© 2013 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of
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be expected because of the lack of C-terminal amidation
(Fisher et al. 1996), demonstrating that post-translational
modiﬁcations need to be taken into account when re-
targeting the botulinum protease toward desired cells.
To ascertain targeting speciﬁcity we used a monoclonal
anti-SNAP25 antibody (clone SMI81) that recognizes both
native and cleaved products. Among the recombinant
chimeras, CNTF and EGF again were the most active
ligands to direct the botulinum protease into the SH-SY5Y
cells (Fig. 3c). The efﬁcacy of these two growth factors was
also conﬁrmed with the SMI81 monoclonal antibody when
rat cortical neuronal cultures were treated with the full range
of stapled botulinum constructs (Figure S1). Next, we
performed competition experiments using the native ligands.
Fig. 3d (left panel) shows that the application of 4 lM
human CNTF 15 min before the addition of 20 nM BoT-
CNTF to SH-SY5Y cells resulted in a reduced cleavage of
SNAP25. Similarly, application of 10 lM human EGF
15 min before the addition of 20 nM BoT-EGF to Min6
cells led to reduction in SNAP25 cleavage (Fig. 3d, right
panel). The two targeted BoTs thus compete for binding sites
with the native growth factors, indicating that ligand
interactions with cognate EGF and CNTF receptors are
necessary for the observed botulinum activity.
Botulinum–based inhibition of hormone release
Because SNAP25 is obligatory for calcium-dependent exo-
cytosis, the observed cleavage by the botulinum protease
should result in inhibition of secretion of hormones and
neurotransmitters. Pheochromocytoma cells serve as a model
of regulated secretion and represent a valid medical target as
a result of their excessive release of catecholamines (Martin
and Grishanin 2003). We incubated PC12 cells in the
presence of 20 nM BoT-EGF, or untargeted BoT, for 42 h
and then measured the uptake and release of 3H-catechol-
amine. The BoT molecules did not affect total 3H-catechol-
amine uptake (Figure S2), whereas BoT-EGF caused a 34%
reduction in K+-induced catecholamine secretion compared
to control (Fig. 4a, p < 0.01). In contrast, Bitox at 20 nM
concentration did not attenuate the release of catecholamine
from PC12 cells (data not shown). In a previous study, very
high doses of BoNT/A were required to lower catecholamine
release which can be explained by the lack of high afﬁnity
binding sites on PC12 cells for the native botulinum
molecule (Shone and Melling 1992). We also evaluated the
action of CRH-targeted botulinum protease on secretion of
ACTH from pituitary AtT-20 cells, a model for Cushing’s
disease (Bangaru et al. 2010). Cells were pre-treated with
stapled BoT-Staple-CRH or an untargeted control (BoT-
(a)
(b)
(c)
(d)
Fig. 3 Targeting of neuroendocrine tumor cells using recombinant
botulinum constructs. (a) Coomassie-stained sodium dodecyl sulfate–
polyacrylamide gel electrophoresis gel showing recombinant proteins
consisting of Botulinum enzymatic and translocation domains (BoT)
fused directly to the indicated targeting domains: ciliary neurotrophic
factor (CNTF); tumor necrosis factor a (TNF-a); epidermal growth
factor (EGF), and substance P (SP). BoT is a recombinant protein
carrying the botulinum protease and the translocation domain without a
targeting moiety. (b) Immunoblot showing the botulinum activity of
recombinant botulinum molecules (10 nM) as revealed using the
cleaved SNAP25 antibody. Total syntaxin immunoreactivity was used
as a loading control. (c) Monoclonal anti-SNAP25 antibody (clone
SMI81) was used to conﬁrm speciﬁcity of botulinum retargeting using
CNTF and EGF to SH-SY5Y cells. (d) Bar charts showing that
application of CNTF on SH-SY5Y or EGF on Min6 cells lead to a
decrease in cleaved SNAP25 caused by BoT-CNTF and BoT-EGF,
respectively ( SD). Representative immunoblots are shown below
the bar charts.
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Staple) at 10 nM for 42 h. Fig. 4b shows that the AtT-20
cells exhibited a high rate of basal secretion of ACTH that
was signiﬁcantly reduced following application of BoT-
Staple-CRH as measured by enzymatic immunoassay
(p < 0.005). Furthermore, ACTH release triggered by native
CRH was reduced by 36% following treatment with BoT-
Staple-CRH compared to the untargeted control (p < 0.005).
No reduction in the release of ACTH was observed when
AtT-20 cells were treated with the Bitox control (10 nM,
data not shown).
Selective targeting of neuronal populations
Ligand-targeted BoTs may become useful not only in
treatments of hypersecretory disorders but also for delineat-
ing and blocking speciﬁc neuronal subpopulations. We
therefore investigated the ability of growth factor-directed
BoTs to target rat cortical neurons in culture. BoT-affected
neurons were visualized with the antibody against the
(a)
(b)
Fig. 4 Inhibition of exocytosis using retargeted botulinum molecules.
(a) A signiﬁcant reduction in KCl-stimulated 3H-norepinephrine release
was observed when PC12 cells were pre-treated with Botulinum
enzymatic and translocation domains (BoT)-epidermal growth factor
compared to untreated cells (*p < 0.01) or untargeted BoT
(***p < 0.005). (b) A signiﬁcant reduction in ACTH release was
observed when AtT-20 cells were treated with BoT-Staple- corticotropin
releasinghormone (CRH) compared tountreatedcells both in the caseof
basal (**p < 0.02) and stimulated secretion (bovine CRH, bCRH;
***p < 0.005). BoT-Staple-CRHcaused a signiﬁcant reduction in ACTH
release when compared to the untargeted BoT-Staple in the case of
basal (**p < 0.02) and bCRH-stimulated secretion (*p < 0.05).
(a)
(b)
(c)
Fig. 5 Differential targeting of neuronal populations by epidermal
growth factor (EGF)- and ciliary neurotrophic factor (CNTF)-targeted
botulinum molecules. (a) Confocal images of E18 rat cortical neurons
treated with native BoNT/A, Botulinum enzymatic and translocation
domains (BoT)-EGF and BoT-CNTF. The left column shows neurons
immunostained with a Map2ab antibody (green), the middle column
shows cleaved SNAP25 (red) and the right column shows the merge
images, also containing nuclear Hoechst staining (blue). Horizontal
bar: 100 lm (b) Immunoblot showing SNAP25 cleavage triggered by
native botulinum neurotoxin (BoNT/A) and retargeted recombinant
fusions. (c) Bar chart showing relative colocalization of the Map2ab
and cleaved SNAP25 elicited by native and retargeted botulinum
molecules (correlation coefﬁcient multiplied by the signal intensity;
 SD). Signiﬁcant differences can be seen between BoNT/A and BoT-
EGF (*p < 0.005), BoNT/A and BoT-CNTF (**p < 0.03), as well as
BoT-CNTF and BoT-EGF (*p < 0.005). BoT-CNTF preferentially
delivers the botulinum protease into mature Map2ab-positive neurons
whereas BoT-EGF acts preferentially on Map2ab-negative neuronal
precursor cells.
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cleaved SNAP25 (Fig. 5a). We used the dendritic marker
Map2ab to distinguish mature neurons from neuronal
precursors. The native BoNT/A cleaves the intracellular
SNAP25 in both mature neurons (Map2ab+ cells) as well as
neuronal precursors (Map2ab-/SNAP25+ cells) (Fig. 5a, top
row). When assessed by western immunoblotting using the
SMI81 anti-SNAP25 antibody, an almost total SNAP25
cleavage can be observed in the case of native BoNT/A, as
for previously reported Bitox (Darios et al. 2010) (Fig. 5b).
In contrast, only a proportion of SNAP25 is cleaved by
BoT-EGF and BoT-CNTF (Fig. 5b). BoT-EGF (10 nM)
predominantly targeted Map2ab negative cells, that is,
immature neurons (Fig. 5a, second row) suggesting that
neuronal stem cells together with transit amplifying cells and
neuroblasts can be targeted by the BoT-EGF (Moyse et al.
2008). An abundant amount of cleaved SNAP25 signal can
be evidenced in a proliferating ‘neurosphere’ (white arrow;
Figure S3) where the neuronal precursor cells should carry
abundant EGF receptors (Reynolds and Weiss 1992; Her-
mann et al. 2006; Moyse et al. 2008). Interestingly, when
BoT-CNTF was applied to neocortical cultures, we mostly
detected the cleaved SNAP25 signal in Map2ab-positive
cells (Fig. 5a, third row). This agrees well with the
expression in mature neurons of the CNTF receptor, which
promotes differentiation, cell survival, and neurite outgrowth
(Richardson 1994; Sleeman et al. 2000). The absence of
cleaved SNAP25 in the control experiment (Fig. 5a, fourth
row) conﬁrmed the antibody speciﬁcity in cell immunostain-
ing experiments. Fig. 5c shows quantiﬁcation of co-locali-
zation of cleaved SNAP25 with Map2ab as observed by
immunocytochemistry. BoT-CNTF has a high degree of
colocalization with Map2ab, which signiﬁcantly outweighs
the native toxin (p < 0.03) and BoT-EGF (p < 0.005),
suggesting targeting of predominantly mature neurons.
BoT-EGF, on the other hand, has an inverse relationship
with Map2ab+ cells and thus mainly targets precursor cells
(p < 0.005).
Discussion
Together, our results demonstrate that new ligands can
substitute the botulinum receptor-binding domain and allow
targeting of distinct neurons and cells of neuroendocrine
origin. Recently, increasing efforts have been directed toward
modifying several types of botulinum neurotoxins for
treatment of diverse hypersecretory disorders including
inﬂammation, asthma, chronic pain, and NETs, such as
acromegaly and Cushing’s disease (Chaddock et al. 2004;
Foster 2005; Chaddock and Marks 2006; Foster et al. 2006;
Chen and Barbieri 2009; Foster and Chaddock 2010; Pickett
and Perrow 2011; Somm et al. 2012). Chimeric proteins
have been designed with the aim of lowering systemic
botulism toxicity and redirecting the botulinum activity
toward the desired cells, for example the botulinum type C
protease (Chaddock et al. 2000a,b; Foster et al. 2006).
Currently the vast majority of botulinum-based therapies
utilize speciﬁcally type A botulinum enzyme (e.g. BOTOX,
Dysport, Xeomin preparations), which allows the longest
known blockade of secretion, lasting up to 6 months. Here,
we addressed the possibility of retargeting type A botulinum
enzyme using a new approach – the protein stapling
technique (Ferrari et al. 2012). When designing new chime-
ric proteins, direct fusion of protein modules can lead to
misfolding, proteolytic degradation, and low yields. Recom-
binant fusion of chimeric proteins also has limitations
because of the unidirectional nature of protein translation
(N–C). Design of new biological molecules thus would
beneﬁt from a prior functional testing of separate units,
which can be then combined on demand (Smith and Hecht
2011; Ferrari et al. 2012). Here, functional proteins carrying
necessary linkers were produced separately, stapled together
using a short synthetic peptide and then tested for their
functionality (Darios et al. 2010). We now show that this
approach allows successful delivery of the type A botulinum
protease into speciﬁc neuroendocrine cells using both
neuropeptides and growth factors.
Different cell types express a mosaic of cell-surface
receptor including G-protein coupled receptors (GPCRs)
and tyrosine kinase receptors that bind neuropeptides and
growth factors. These receptors can internalize into the cell
upon ligand binding and thus may be compatible for the
delivery the botulinum molecules into the cytosol. Indeed,
neuropeptides and growth factors have been used to deliver
various cargoes into speciﬁc cells, but signiﬁcant obstacles
hamper utilization of these ligands (Fisher et al. 1996; Langer
and Beck-Sickinger 2001; Middleton and Kellam 2005;
Foster et al. 2006; Zhou et al. 2007; Frankel et al. 2009). It is
well known that the binding activity of neuropeptides and
growth factors often depends on post-translational modiﬁca-
tions that could be difﬁcult to implement. Another problem
relates to poor expression of extracellular ligands in bacteria
when designing new therapeutic chimeras based on bacterial
proteins such as the botulinum protease.
Here, we investigated TNFa, CNTF, EGF, dermorphin,
dynorphin 17, substance P, somatostatin, corticotropin-
releasing hormone, and the native botulinum receptor-
binding domain for their ability to direct the botulinum
protease into a variety of neuroendocrine tumor cells. Each
ligand was prepared with a linker sequence necessary for the
stapling reaction. Upon ligand-dependent internalization into
acidifying endosomes, the translocation domain enables the
SNAP25 protease to reach and cleave its substrate (Harper
et al. 2011). We found that EGF, CNTF, and CRH ligands
were the most effective in delivering the botulinum protease
into neuroendocrine cells. When we directly fused the wide
range of ligands to the BoT unit we observed that only half of
the ligands yielded workable recombinant fusions. EGF and
CNTF direct fusions were as active on the neuroendocrine
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tumor cells as the stapled products in terms of selectivity and
cleavage of SNAP25 (Figs. 2 and 3). The selectivity of our
ligand-directed BoT molecules toward their cognate receptor
systems was evidenced by reduction in SNAP25 cleavage in
the presence of their native hormones. Overall, protein
stapling allowed construction of a wider range of active
botulinum products with varied structural diversity and better
yields. Modiﬁcations such as C-terminal amidation of
substance P, free N-terminus of the dermorphin peptide are
important in targeting efﬁcacy (Fisher et al. 1996). Using
double targeting domains (2 9 SP), on the other hand, can
aid statistical rebinding of ligands and receptor dimerization
can lead to a better penetration of the botulinum enzyme. In
our attempts, we only observed an improvement in SNAP25
cleavage when using C-terminally amidated substance P or
dermorphin when stapled to the botulinum protease. These
observations are of interest because substance P and
dermorphin have been used to target neuronal circuits
involved in pain processing (Nichols et al. 1999; Ossipov
et al. 2010). We envisage that botulinum-stapled substance P
and dermorphin could provide long-term but reversible
control of chronic pain states. Further exploration of
secondary modiﬁcations and combinations of various ligands
might yield improved targeting in future studies.
The BoT-EGF molecule developed in this study could be a
prototype medicine for treatment of pheochromocytomas.
These adrenal neoplasms are unresponsive to radio- or
chemotherapy, and only treatable by surgery. Furthermore,
during ablative operations, the neoplasms release unpredict-
able amounts of catecholamines, requiring constant monitor-
ing and pharmacological ﬁne-tuning to stabilize the patients
(Cryer 1992; Garg and Banitt 2004; Lin et al. 2007; Low
et al. 2012). Given that, the BoT-induced SNAP25 cleavage
results in a secretory blockade, BoT-EGF could be beneﬁcial
not only for palliative care prior to surgery but also as a long-
duration pharmacological intervention of non-malignant
pheochromocytomas.
It has been estimated that up to 5% of the human
population suffers from endocrine disorders (Golden et al.
2009) and long-term strategies to modulate hormonal
secretion would be beneﬁcial when invasive surgeries are
unsuccessful or are associated with intolerable side effects.
This study suggests that a wide range of long-acting
botulinum therapies can become available when utilizing
the protein stapling technology. Finally, we demonstrated in
this study that the retargeted versions of botulinum protease
can be used to dissociate separate populations of neurons.
This opens a door for selective and tailored neuronal
silencing in future research applications.
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Figure S1. Immunoblot showing SNAP25 cleavage in E18 rat
cortical neurons treated with the indicated stapled botulinum
constructs as revealed using SMI81 antibody recognizing both
intact and cleaved SNAP25.
Figure S2. Bar chart showing similar 3H-catecholamine uptake
(counts per minute, CPM) by PC12 cells ( SD) treated or not with
the indicated botulinum molecules.
Figure 3. A magniﬁed region indicated by the white arrow in the
panel 5a showing presence of cleaved SNAP25 in the ‘neurosphere’
following treatment with BoT-EGF.
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